OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
Martin Vališ, Anat Achiron, Hans Hartung, et al.
Drugs in R&D (2023) Vol. 23, Iss. 4, pp. 331-338
Open Access | Times Cited: 13
Martin Vališ, Anat Achiron, Hans Hartung, et al.
Drugs in R&D (2023) Vol. 23, Iss. 4, pp. 331-338
Open Access | Times Cited: 13
Showing 13 citing articles:
How do sphingosine-1-phosphate affect immune cells to resolve inflammation?
Gehui Sun, Bin Wang, Xiaoyu Wu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Gehui Sun, Bin Wang, Xiaoyu Wu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data
Nunzia Balzano, Raffaella Di Napoli, Federica Fraenza, et al.
Pharmacological Reports (2025)
Open Access
Nunzia Balzano, Raffaella Di Napoli, Federica Fraenza, et al.
Pharmacological Reports (2025)
Open Access
Brain health – time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report
Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106456-106456
Closed Access
Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106456-106456
Closed Access
Uma revisão narrativa da literatura sobre o tratamento da esclerose múltipla
Leonardo Pereira Levada, Milena Beatriz Benício Neves, Ana Beatriz Teles de Almeida, et al.
Brazilian Journal of Implantology and Health Sciences (2024) Vol. 6, Iss. 2, pp. 1785-1796
Open Access | Times Cited: 2
Leonardo Pereira Levada, Milena Beatriz Benício Neves, Ana Beatriz Teles de Almeida, et al.
Brazilian Journal of Implantology and Health Sciences (2024) Vol. 6, Iss. 2, pp. 1785-1796
Open Access | Times Cited: 2
Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities
Haisong Li, Meng Guan, Ning-Ning Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117011-117011
Open Access | Times Cited: 2
Haisong Li, Meng Guan, Ning-Ning Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117011-117011
Open Access | Times Cited: 2
Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking
Chao Li, Chuanjun Zhuo, Xiaoyan Ma, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Chao Li, Chuanjun Zhuo, Xiaoyan Ma, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Repurposing the multiple sclerosis drug Siponimod for osteoporosis treatment
Sitao Hu, Yangyang Hu, Zenglin Tan, et al.
European Journal of Pharmacology (2024) Vol. 974, pp. 176630-176630
Open Access | Times Cited: 1
Sitao Hu, Yangyang Hu, Zenglin Tan, et al.
European Journal of Pharmacology (2024) Vol. 974, pp. 176630-176630
Open Access | Times Cited: 1
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series
Antonella Bianco, Tommaso Guerra, Francesca Caputo, et al.
Clinical Neurology and Neurosurgery (2024) Vol. 245, pp. 108475-108475
Closed Access | Times Cited: 1
Antonella Bianco, Tommaso Guerra, Francesca Caputo, et al.
Clinical Neurology and Neurosurgery (2024) Vol. 245, pp. 108475-108475
Closed Access | Times Cited: 1
Optical coherence retinal tomography as a prognostic biomarker of multiple sclerosis progression
T. V. Shchukina, Г. Н. Бисага, V. A. Malko, et al.
Russian neurological Journal (2024) Vol. 29, Iss. 3, pp. 16-23
Closed Access
T. V. Shchukina, Г. Н. Бисага, V. A. Malko, et al.
Russian neurological Journal (2024) Vol. 29, Iss. 3, pp. 16-23
Closed Access
Markers of Secondary Progression in Multiple Sclerosis
André Pessoa Silva de Bastos, Mafalda Soares, Joana Guimarães
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105881-105881
Open Access
André Pessoa Silva de Bastos, Mafalda Soares, Joana Guimarães
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105881-105881
Open Access
Impact of Siponimod on Clinical and Radiological Parameters of Secondary Progressive Multiple Sclerosis: A Real-World Prospective Study
Konstantina Stavrogianni, Dimitrios K. Kitsos, Vasileios Giannopapas, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 6, pp. 591-591
Open Access
Konstantina Stavrogianni, Dimitrios K. Kitsos, Vasileios Giannopapas, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 6, pp. 591-591
Open Access
Multiple Sclerosis Pharmacology of Disease Modifying Therapies
Anza B. Memon, Ahmed Elrefaey, Robert P. Lisak, et al.
Elsevier eBooks (2024)
Closed Access
Anza B. Memon, Ahmed Elrefaey, Robert P. Lisak, et al.
Elsevier eBooks (2024)
Closed Access
Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up
Rebecca Ludwig, Bimala Malla, Maria Höhrhan, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 261-261
Open Access | Times Cited: 1
Rebecca Ludwig, Bimala Malla, Maria Höhrhan, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 261-261
Open Access | Times Cited: 1
